Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyValentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2012Cited by 368
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancerWolfgang Janni, Christos Papadimitriou, Tomasz Sarosiek et al.|Breast Cancer Research and Treatment|2014Cited by 27
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancerWolfgang Janni, Christos Papadimitriou, Tomasz Sarosiek et al.|The Breast|2015Cited by 11
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).Christos Papadimitriou, Wolfgang Janni, Tomasz Sarosiek et al.|Journal of Clinical Oncology|2013Cited by 6
Brain and tumor penetration of carbon-11–labeled lapatinib ([<sup>11</sup>C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).Azeem Saleem, R. Charles Coombes, Louise Downie et al.|Journal of Clinical Oncology|2013Cited by 5